2026-09-02 · Gold Kelly (Chief Financial Officer) · BUY
2026-08-31 · Schwab Andrew J. (Director) · SELL
2026-08-26 · Schwab Andrew J. (Director) · SELL
2026-08-21 · Schwab Andrew J. (Director) · SELL
INSTITUTIONAL OWNERSHIP
Institutional holders63
Shares held49,661,522
Value$220.19M
Percent of shares outstanding79.14%
As of quarter end2026-06-30
RECENT NEWS
Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day Transcript
Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day - Slideshow
CAMP: CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder